From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction.

These data indicate that "prolonged [TNF inhibitor] treatment plays a protective role in PsA development in severe psoriasis patients," the researchers wrote. This is important, in that some previous ...

Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque psoriasis, with one producing a PASI90 response in 61% of patients at 52 weeks.

The efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis are currently being evaluated in the Phase 3 ONWARD clinical program, which consists of two parallel ...

Alumis Inc. completed patient enrollment in its Phase 3 trials for ESK-001, targeting moderate-to-severe plaque psoriasis. Quiver AI Summary. Alumis Inc. has announced the successful completion of ...

This multicenter, randomized, double-blind, placebo-controlled trial randomized (1:1:1:1) 145 Chinese patients with moderate to severe plaque psoriasis to receive AC-201 25mg BID, 50mg BID or ...

The efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis are currently being evaluated in the Phase 3 ONWARD clinical program, which consists of two parallel ...